← Back to Clinical Trials
Recruiting NCT07125170

NCT07125170 Immersive Virtual Reality in Cognitive Rehabilitation of Patients With Post-Stroke Cognitive Impairment

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07125170
Status Recruiting
Phase
Sponsor University of Chile
Condition Stroke
Study Type INTERVENTIONAL
Enrollment 20 participants
Start Date 2025-08-06
Primary Completion 2026-05-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Kinesix XR on Meta Quest 3

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 20 participants in total. It began in 2025-08-06 with a primary completion date of 2026-05-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This pilot study aims to evaluate the feasibility of implementing immersive virtual reality (VR) in cognitive rehabilitation for adults with post-stroke cognitive impairment receiving outpatient therapy. Participants will use a head-mounted display and interactive software to engage in gamified cognitive exercises that simulate memory, attention, and executive function tasks. The intervention consists of 10 sessions, delivered two to three times per week over a period of approximately four weeks. The study will assess multiple feasibility indicators, including the recruitment rate based on eligibility criteria, the safety and tolerability of VR sessions for participants, and the usability and satisfaction reported by occupational therapists administering the intervention. Additionally, exploratory outcomes include changes in global cognition and specific cognitive domains, as well as self-reported quality of life. Adverse effects related to VR use will be tracked. This pilot study will help inform the design and implementation of future, larger-scale clinical trials.

Eligibility Criteria

Inclusion Criteria: * Patients over 18 years of age * Patients with a cerebrovascular accident of any etiology with less than 3 months of progression * Patients with mild to moderate cognitive impairment post-stroke (impairment in at least one cognitive domain) * MoCA score of less than 24 points * Referred for cognitive rehabilitation at the Occupational Therapy Unit of HCUCH Exclusion Criteria: * Patients with refractive errors that prevent the use of the headset * Patients with any type of aphasia that prevents the administration of the MoCA test * Patients with severe psychiatric disorders (presence of psychotic symptoms or derealization) * Patients with severe motor impairments (lack of trunk control or global strength of both upper limbs \< M3)

Contact & Investigator

Central Contact

Natalia Gattini, MD

✉ ngattini@hcuch.cl

📞 +56989019110

Frequently Asked Questions

Who can join the NCT07125170 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07125170 currently recruiting?

Yes, NCT07125170 is actively recruiting participants. Contact the research team at ngattini@hcuch.cl for enrollment information.

Where is the NCT07125170 trial being conducted?

This trial is being conducted at Independencia, Chile.

Who is sponsoring the NCT07125170 clinical trial?

NCT07125170 is sponsored by University of Chile. The trial plans to enroll 20 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology